Trekrezan: defined composition and minor components — RU2806642C1
Олег Викторович Жеребцов, Ерануи Феликсовна Агаджанян, Яна Александровна Каменчук · 2023 · RU2806642C1 · patent family RU2806642C1
Published 2023-11-02.
Reported patent results
Narrative findings; numerical extraction incomplete
The disclosure claims faster dissolution and earlier clinical recovery, but does not provide a sufficiently clear completed-trial outcome table.
Trekrezan-related composition development with dissolution and immune assays; a clinical influenza section mixes prospective protocol language and concluding effectiveness assertions.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Dissolution comparison | The composition is described as dissolving faster than the reference preparation | A formulation result; no transcribed dissolution curve or comparative exposure estimate |
| Clinical assertion | Improvement stated by day 3 and complete recovery by day 9, versus residual symptoms with the reference | No verified analyzed denominator, arm-level recovery counts or uncertainty supplied |
| Completion ambiguity | Much of the clinical section describes what patients “will receive” | A proposed protocol is not evidence that its outcome was achieved |
Clinical effectiveness is not established by the closing assertion. Composition-specific dissolution findings cannot validate all Trekrezan products or isolate an additive’s benefit.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The claims concern a specified Trekrezan-related composition, including defined minor constituents.
A composition with particular constituents is narrower than the base molecule; efficacy should not be assigned to impurities without supporting experiments.
- Publication
- RU2806642C1 ↗ · 2023-11-02
- Earliest priority / filing
- Not established / 2023-04-07
- Original applicant / assignee
- Общество с ограниченной ответственностью "Гротекс"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Adaptogenic, immunomodulating and anti-viral pharmaceutical composition of oxyethylammonium methylphenoxyacetate
Inventors: Олег Викторович Жеребцов; Ерануи Феликсовна Агаджанян; Яна Александровна Каменчук.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- A composition with particular constituents is narrower than the base molecule; efficacy should not be assigned to impurities without supporting experiments.
- Clinical effectiveness is not established by the closing assertion. Composition-specific dissolution findings cannot validate all Trekrezan products or isolate an additive’s benefit.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-RU2806642C1. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Олег Викторович Жеребцов, Ерануи Феликсовна Агаджанян, Яна Александровна Каменчук. Trekrezan: defined composition and minor components — RU2806642C1 RU2806642C1 · patent family RU2806642C1 2023.
Molekul research summary: https://molekul.io/research/patent-ru2806642c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry